Jessie J admitted to hospital for infection just weeks after breast cancer surgery
However, the 37-year-old shared that doctors instead discovered an 'infection' and 'a little fluid', weeks after undergoing surgery for breast cancer.
Jessie said she has since discharged herself from the same hospital where she was treated after breast cancer surgery, announcing in July that she had since seen 'no cancer spread'.
Jessie J says breast cancer surgery 'isn't a speedy recovery and it isn't meant to be'
In a post on Instagram, the Price Tag singer told her followers: 'Six weeks post surgery and I was back in the same ward I was after my surgery. Not expected or planned.
'I had and still have symptoms that pointed towards a blood clot on the lung, it is not a blood clot thank god.
'They ran a lot of tests, which ended up showing I have an infection (still trying to figure out what) and a little fluid on my lungs.
'Finding it hard to breathe in, but I discharged myself last night (I hate being in hospital) and will continue the investigation as an outpatient.'
She went on to say it was 'frustrating' that her career plans had to change due to her surgery and hospital visits, and added that she had been 'working so hard to get to this point and excited to do it all'.
When to See Your GP About Cancer
Jessie continued: 'I know for me, the true hard journey of this whole thing physically was the day I went into surgery.
'The recovery physically is far from quick or easy, and mentally it's been the most challenging time for me, especially as a mum with a toddler and being unable to be the mother I usually am.'
The former coach on The Voice said her visit to hospital was a 'reminder to myself to slow down' even though she felt she was already at a slow pace.
Recommended reading:
Singer Jessie J diagnosed with 'early breast cancer' and reveals surgery plans
Freddie Flintoff praises NHS staff who cared for him after serious car crash
Michael Palin 'slightly unsteady' as he admits he's 'prepared for death'
Jessie added: 'This isn't a speedy recovery and it isn't meant to be.
'As an ADHD Aries, fire breathing dragon t-rex, I can do it myself, I'm always ok woman. That slow pace has been a hard reality to accept to be honest.
'I love moving and working and being up and active but I can't be right now, and that's what it is, and I am finding the strength knowing that all can be adjusted to align with a slower pace and the support of my very small inner support circle.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Justin Timberlake Jokes He's 'Not Doing S--- Today' as He Returns Home from Tour amid Lyme Disease Diagnosis
NEED TO KNOW Justin Timberlake is "not doing s---" as he relaxes at home, following the end of his two-year Forget Tomorrow World Tour and his Lyme disease diagnosis In an Instagram Stories photo posted Aug. 4, Timberlake, 44, could be seen posing in a sweatshirt that reads: "I'm not doing s--- today. Mission accomplished" Timberlake shared the news about his recent diagnosis with fans on July 31Justin Timberlake is spending his time relaxing at home, following the end of his two-year Forget Tomorrow World Tour and his Lyme disease diagnosis. In an Instagram Stories photo posted on Monday, Aug. 4, the NSYNC alum, 44, could be seen posing in a sweatshirt that reads: "I'm not doing s--- today. Mission accomplished," as he sticks his tongue out for the camera. Related: Timberlake shared the news about his Lyme disease diagnosis with fans in his Instagram Stories and in his feed on Thursday, July 31. "I've been battling some health issues, and was diagnosed with Lyme disease — which I don't say so you feel bad for me — but to shed some light on what I've been up against behind the scenes," the 'SexyBack' singer wrote. "If you've experienced this disease or know someone who has — then you're aware: living with this can be relentlessly debilitating, both mentally and physically." Transmitted from the bite of an infected tick, Lyme disease can cause flu-like symptoms such as headaches, joint pain, fatigue, or a fever, per the Cleveland Clinic. It's often diagnosed by a rash resembling a bullseye around on the tick bite, and can be confirmed with a Lyme disease blood test. The announcement came just as he ended the Forget Tomorrow World Tour. Earlier in the tour, Timberlake canceled or postponed various shows due to an ongoing back injury, bronchitis and laryngitis, and an ankle injury. Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. A number of the musician's friends and family members have come out in support of him amid the announcement, including his wife Jessica Biel. A family source told PEOPLE soon after Timberlake's announcement that the news has brought Timberlake "clarity" and that Biel has been "incredibly supportive" of him during this time. "He's not 20 anymore. But when his symptoms worsened, he realized something deeper was going on," the source said. "He pushed through for months before finally getting answers. The Lyme disease diagnosis brought clarity to a series of unexplained issues that he's been quietly dealing with." As the insider explained, Timberlake's focus is now on treatment and recovery following the conclusion of his tour. "He's taking it seriously. The plan is to rest, spend time with Jess and the kids and do everything he can to heal," the family source said of the couple, who are parents to sons Silas, 10, and Phineas, 5. "He loved touring and being back onstage, but he's also relieved it's over. Now he can focus on his health." Read the original article on People
Washington Post
3 hours ago
- Washington Post
The worst way to achieve herd immunity is demonizing anti-vaxxers
Monica Hesse described in her July 15 op-ed, 'There's no vaccine for this,' her dismay at the state of U.S. measles vaccination rates. She fears that the loss of herd immunity will harm those who aren't able to be vaccinated, but wrote that 'what makes me worry most is that the people causing the collapse in herd immunity do not seem to understand that.' That framing reveals an unfortunately common lack of understanding of those 'causing the collapse.'
Yahoo
4 hours ago
- Yahoo
This High-Yield Dividend Stock Is Staging a Comeback. Should You Buy Shares Now?
When a 'boring' healthcare stock posts a 7% surge intraday, investors take notice. That's exactly what happened when CVS Health delivered its second-quarter 2025 earnings on July 31. The healthcare giant's adjusted earnings of $1.81 per share crushed analyst estimates of $1.45, while revenue climbed 8.4% year-over-year to $98.92 billion. This impressive beat comes at a time when the S&P 500 Healthcare Index ($SRHC) fell 12% over the past year, significantly trailing the broader S&P 500 Index's ($SPX) gain of 18.2%. CVS itself endured a particularly volatile 2024, cutting its earnings guidance three times and watching its stock plummet over 40% as medical costs in its Aetna insurance division spiraled higher than expected. More News from Barchart This Blue-Chip Dividend Stock Is Stuck in the Tariff Crosshairs. Can Cost Cuts Save the Day? Worried About a Stock Market Crash? These Dividend Stocks Can Help You Ride It Out Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Yet, with its latest results stirring up fresh optimism, it's worth asking - is this high-yield dividend stock at the start of a legitimate comeback, or was the Q2 surprise - like last Thursday's intraday rally - just a fleeting moment of glory? Let's dive in. CVS's Latest Q2 Financial Results CVS Health (CVS), a retail pharmacy, healthcare services, and insurance company, boasts a market capitalization of approximately $79 billion. The company's high-yield credentials are anchored by a robust annual dividend rate of $2.66, delivering shareholders an above-market dividend yield of 4.26%, and elevating CVS into the upper echelon of dividend stocks. Shares have surged 37.1% year-to-date, but CVS stock trades at just 10.05x forward adjusted earnings - a generous discount to the healthcare sector median of 16.86x - and boasts a similarly low price/earnings-to-growth (PEG) ratio of only 0.59x. This lower multiple suggests the market still underappreciates CVS's earnings momentum and long-term growth prospects. In the July 31 Q2 report, total revenues climbed to $98.9 billion, marking an 8.4% year-over-year gain that eclipsed analysts' forecasts. While second-quarter GAAP diluted EPS landed at $0.80, down from $1.41 a year earlier, this was mainly due to two significant litigation charges tied to legacy business issues. Perhaps more importantly, management reported $6.5 billion in cash flow from operations year-to-date, reinforcing both dividend security and strategic agility. The company's earnings power is being driven by improved performances in its Health Care Benefits and Pharmacy & Consumer Wellness segments, offsetting short-term headwinds in Health Services. CVS's Next Strategic Act CVS inked a pivotal deal with Rite Aid, agreeing to acquire select prescription files and store locations across 15 states. This acquisition stands to significantly broaden CVS's market reach while promising meaningful operational synergies. This could be a crucial lever as CVS aims to build scale and streamline retail pharmacy operations at a time when consumer patterns are evolving fast. In another move to future-proof its business, CVS Health committed a staggering $20 billion investment over the next decade to overhaul healthcare delivery, with a focus on harnessing advanced technology and achieving real interoperability across its ecosystem. This is a long-term wager on connecting care in ways that competitors haven't matched. May 2025 brought another headline-worthy shift: CVS Caremark struck an exclusive partnership with Novo Nordisk (NVO), designating Wegovy as the preferred GLP-1 weight loss drug on all Caremark standard formularies starting July 1. This decision impacts tens of millions of Caremark beneficiaries and, at the same time, removes Eli Lilly's (LLY) Zepbound from CVS's standard list. CVS Pharmacy is now also the inaugural retail pharmacy in Novo's NovoCare network, offering the in-demand Wegovy at a sharply competitive $499 per month for cash-paying customers across all 9,000 CVS locations. Analysts' Consensus on CVS The average consensus among Wall Street analysts is strikingly bullish, forecasting earnings per share of $1.42 for the current quarter, up sharply from $1.09 a year ago, and $6.37 for the full fiscal year, compared to $5.42 last year. That's a growth rate estimate of +30.28% for the quarter and +17.53% for the year,. Backing up this optimism, CVS management hiked its outlook, boosting the full-year adjusted EPS guidance to a range of $6.30 to $6.40 from a prior $6.00 to $6.20. At the same time, the company expects at least $7.5 billion in operating cash flow, up from its earlier $7.0 billion forecast, and offered refined GAAP diluted EPS guidance between $3.84 and $3.94. Perhaps most compelling for prospective investors, nearly three-quarters of the 23 analysts in coverage rate CVS a 'Strong Buy.' The mean analyst price target is $79.41, pointing to a promising 29.2% upside potential from CVS's current price. Conclusion With the majority of analysts labeling CVS a 'Strong Buy' and nearly 30% upside baked into price targets, it's hard to ignore the opportunity here. CVS checks the boxes for value, growth, and high yield, all wrapped in a comeback narrative the market loves. At current levels, the stock could be a compelling value pick for yield hunters as its turnaround gains traction. However, given its placement across policy-sensitive sectors like healthcare and insurance, investors should be prepared for potential headline-driven volatility along with that passive income. On the date of publication, Ebube Jones did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
